Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-26-003910
Filing Date
2026-01-13
Accepted
2026-01-13 16:05:03
Documents
8
Period of Report
2026-01-13

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0272506-6k_chinasxt.htm 6-K 17966
2 FORM OF PRE-FUNDED WARRANT ea027250601ex4-1_chinasxt.htm EX-4.1 114631
3 OPINION OF CAMPBELLS ea027250601ex5-1_chinasxt.htm EX-5.1 26041
4 SECURITIES PURCHASE AGREEMENT ea027250601ex10-1_chinasxt.htm EX-10.1 253950
5 PLACEMENT AGENCY AGREEMENT ea027250601ex10-2_chinasxt.htm EX-10.2 205617
6 PRESS RELEASE DATED JANUARY 9, 2026 ea027250601ex99-1_chinasxt.htm EX-99.1 10476
7 GRAPHIC ex5-1_001.jpg GRAPHIC 11391
8 GRAPHIC ex99-1_001.jpg GRAPHIC 25982
  Complete submission text file 0001213900-26-003910.txt   681528
Mailing Address 178 TAIDONG ROAD NORTH TAIZHOU China
Business Address 178 TAIDONG ROAD NORTH TAIZHOU China 8652386298290
China SXT Pharmaceuticals, Inc. (Filer) CIK: 0001723980 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 0331
Type: 6-K | Act: 34 | File No.: 001-38773 | Film No.: 26530105
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)